TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that it has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics supporting... Read More

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it has signed a new contract with a leading biopharmaceutical company to apply its NetraAI platform to a Phase 3... Read More

TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, presented two significant applications of its technology at the International Society for CNS Clinical Trials and Methodology (ISCTM)... Read More

TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a new collaboration focused on glioblastoma (GBM) research. The collaboration, supported by a license to proprietary... Read More

TORONTO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced the appointment of Jan Sedway, Ph.D., as Senior Vice President of Clinical Science. As NetraMark strategically expands its footprint in the pharmaceutical industry, this appointment reinforces... Read More

TORONTO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced it has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform to analyze results from its pivotal Phase III pediatric clinical trial. The agreement covers the... Read More

TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials is pleased to announce that its Chief Executive Officer, George Achilleos, will be attending the 45th Annual Growth Conference hosted by Canaccord Genuity, taking place August 12–14, 2025, in Boston,... Read More

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement. NetraMark, in... Read More

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an... Read More

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on arXiv demonstrating that its flagship AI platform, NetraAI, has substantially outperformed leading large language models, DeepSeek and ChatGPT. NetraAI also outperformed... Read More

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry through streamlined access to actionable analytics uncovered by AI, today announced that NetraMark founder Dr. Joseph Geraci was the lead author on a new publication... Read More

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence (AI) solutions company transforming clinical trial design in the pharmaceutical industry announced the successful completion of its Annual General Meeting of shareholders held on June 9th, 2025. All matters brought before shareholders, as outlined in the... Read More

TORONTO , April 10, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that it will host a shareholder conference call to provide an update on its recent strategic developments, commercial... Read More

TORONTO , April 3, 2025 /PRNewswire/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced a global agreement with Worldwide Clinical Trials ("Worldwide"), a full-service, global contract research organization... Read More

TORONTO , March 10, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is pleased to announce it has received aggregate proceeds of $1,853,054 from the exercise of 4,805,279 common share purchase warrants (the "Warrants") of the Company from... Read More

TORONTO , March 5, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, presented two significant studies at the International Society for CNS Clinical Trials and Methodology (ISCTM) conference, showcasing the power of advanced machine learning in major depressive disorder (MDD) and schizophrenia clinical... Read More

TORONTO , Feb. 25, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces its funded collaboration with the Ontario Brain Institute (OBI) to enhance the analysis of brain imaging and multi-modal data from Major Depressive Disorder (MDD) clinical research to achieve treatment separation in future... Read More

TORONTO , Feb. 18, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces that it will present new data supporting its mathematically augmented machine learning (ML) tools that enhance predictive modeling and patient stratification in psychiatric clinical trials. The data will be presented at the... Read More

TORONTO , Feb. 4, 2025 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, is pleased to highlight recent corporate advancements; including a key leadership appointment, a major pharmaceutical collaboration, a strategic board addition, a strengthened financial position and a new marketing / investor relations... Read More

TORONTO , Dec. 12, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is pleased to announce that it has received aggregate proceeds of $1,161,000 from the exercise of 2,244,606 common share purchase warrants (the "Warrants") and 410,000 stock... Read More

TORONTO , Dec. 11, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce that Angelico Carta , MD, Co-Founder of Worldwide Clinical Trials (Worldwide) will officially consult to NetraMark as Chief Strategy Officer, while continuing... Read More

TORONTO , Dec. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a premier artificial intelligence (AI) company that is transforming clinical trials in the pharmaceutical industry, is proud to announce that it has entered into a pilot collaboration agreement with a Top 5 pharmaceutical company. The pilot is seeking to unlock novel insights and hypotheses... Read More

TORONTO , Oct. 9, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the appointment of P.J. Haley, Executive Vice President, Commercial at Exelixis, Inc. (Nasdaq: EXEL), as a director of the Company, effective October 15th, 2024 . Mr. Haley will be replacing Sheetal Jaitly , who... Read More

Toronto, Ontario--(Newsfile Corp. - October 2, 2024) - NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF) (FSE: 8TV) (the "Company" or "NetraMark") a generative AI software leader in clinical trial analytics, is pleased to announce its participation at the upcoming Cantech Letter Conference on Wednesday, October 9, 2024 in Toronto Ontario. George Achilleos, CEO of NetraMark, will be delivering a corporate presentation, where... Read More

TORONTO , Sept. 11, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce the expansion of its product base to now include a suite of five innovative offerings designed to enhance clinical trial outcomes, support product differentiation, and optimize market access strategies. "In... Read More

TORONTO , Aug. 20, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, provides a third quarter business update and highlights recent accomplishments.\ "At NetraMark, we're proud of the progress we've made, but we also recognize that our journey is just beginning," said George Achilleos , CEO of... Read More

Research project with the National Institute of Mental Health (NIMH) is designed to identify variables characterizing ketamine response, placebo response and adverse events to guide future clinical trials TORONTO , June 10, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV), a generative AI software leader in clinical trial analytics, announces that it has... Read More

Data to be presented at ASCP 2024 demonstrate how NetraAI-generated insights were used to develop the TAP ™ , a novel measure that can be used to identify placebo responders before randomization, resulting in more efficient trials TORONTO , May 28, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV), a generative AI software leader in clinical trial analytics, is... Read More

Insights open the door for potential precision immunotherapy innovation targeting novel pathways and patient enrichment strategies with the potential to improve clinical trial success rates TORONTO , April 10, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces the presentation of new data... Read More

TORONTO , April 5, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders (the "Meeting"), held on March 28, 2024 . Shareholders voted in favour of all matters of business before the Meeting. Each of those matters is set out in detail in the Management Information... Read More

TORONTO , April 4, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) is pleased to announce the appointment of Jeff Huntsman to its strategic advisory board. With his significant industry experience and expertise, Jeff's addition to the advisory board will further strengthen NetraMark's ability to deliver its innovative Artificial Intelligence (AI) based... Read More

Market validation of the NetraAI clinical solution through the signing of five contracts with biopharmaceutical companies Launched NetraAI Lab, enabling biopharmaceutical companies to apply NetraAI to their data rapidly and cost effectively Presented results demonstrating the power of NetraAI to identify novel biomarkers and improve clinical trial success rates at two prominent scientific conferences TORONTO , April 2, 2024... Read More

NetraMark's NetraAI is tasked with identifying inclusion and exclusion criteria that are predicted to drive larger effect and smaller placebo responses in future clinical trials Potential to demonstrate statistically significant efficacy results in future trials using fewer patients and reduce the time and cost needed for product approval TORONTO , March 12, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark")... Read More

Novel machine learning (ML) approach identifies genetic drivers within specific Parkinson's disease (PD) patient subpopulations and uncovers pivotal disease pathways, enhancing understanding of disease and treatment strategies Data presented at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™ 2024) TORONTO , March 11, 2024 /CNW/ - NetraMark Holdings Inc. (the... Read More

TORONTO , Feb. 29, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces that it will present new data demonstrating the potential of its proprietary NetraAI clinical trial solution to generate novel insights into key drivers of Parkinson's disease (PD). The data will be presented in a poster at... Read More

TORONTO , Feb. 27, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces that it has signed a fourth contract in a new indication with a large, publicly listed biopharmaceutical company, pursuant to the Master Service Agreement, previously announced on October 23, 2023 . NetraMark will employ its... Read More

Results presented in two posters at the International Society for CNS Clinical Trials and Methodology (ISCTM) 20th Annual Meeting demonstrate the potential of NetraAI to enable more efficient clinical development of therapies to treat a variety of mental health disorders TORONTO , Feb. 26, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI... Read More

TORONTO , Feb. 15, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces that it will present new data supporting the potential of its proprietary NetraAI clinical trial solution to de-risk clinical trials for neurology therapies by identifying the key variables that drive clinical trial success... Read More

New offering uses NetraMark's NetraAI to analyze customer's clinical data and identify key variables that drive efficacy, toxicity and placebo responses in only four weeks Recommendations based on NetraAI generated insights can enhance drug effect size and statistical significance, providing a validated approach to overcoming the industry's 88% clinical trial failure rate TORONTO , Feb. 12, 2024 /CNW/ - NetraMark Holdings... Read More

TORONTO , Jan. 30, 2024 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, announces that it has signed a third contract with a large publicly listed biopharmaceutical company, pursuant to the Master Service Agreement, previously announced on October 31, 2023. NetraMark will employ its proprietary Attractor... Read More

Newly peer-reviewed, published research demonstrates the power of NetraAI to detect novel and known potential therapeutic targets for amyotrophic lateral sclerosis (ALS) that were not identified using other AI-based methods NetraAI identified well-defined subpopulations that could improve ALS clinical trial outcomes. These results were derived from 116 patients, demonstrating the unique power of the platform compared with... Read More

TORONTO , Dec. 20, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a generative AI software leader in clinical trial analytics, is pleased to announce that it has signed two contracts with a large publicly listed biopharmaceutical company, pursuant to the previously announced Master Service Agreement on October 31, 2023 . NetraMark will employ its proprietary... Read More

TORONTO , Nov. 20, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTCQB: AINMF) a leader in predictive clinical trial analytics, is pleased to announce it has entered into an agreement with FINN Partners, Inc ("FINN Partners"), a global full-service marketing and communications agency with a strong presence in the life sciences sector, to provide public relations services... Read More

TORONTO , Nov. 6, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTCQB: AINMF) is pleased to announce the appointment of Dr. Larry Alphs as its Chief Medical Officer (CMO). Dr. Alphs will play an important role in shaping the company's initiatives, further strengthening its commitment to providing cutting-edge generative AI solutions and improving clinical trial outcomes.... Read More

TORONTO , Oct. 31, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) a leader in predictive clinical trial analytics, is thrilled to announce that it has entered into a Master Service Agreement with a large public listed biopharmaceutical company. The agreement paves the way for collaboration, whereby NetraMark will employ its unique Generative AI technology... Read More

TORONTO , Sept. 19, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) , is pleased to announce that it has closed its previously announced private placement for gross proceeds of $2,000,000 (the " Offering "). Netramark issued 10,000,000 units (each, a " Unit ") under the Offering at a price of $0.20 per Unit, with each Unit consisting of one common share in the... Read More

TORONTO , Sept. 15, 2023 /CNW/ - NetraMark Holdings Inc. (the " Company " or " NetraMark ") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF) announces a clarification to its press release issued September 11, 2023 regarding a non-brokered private placement financing (the " Offering ") of a minimum of 7,500,000 units of the Company (the " Units "), for aggregate gross proceeds of not less than $1.5 million to set out the price of... Read More

TORONTO , Sept. 11, 2023 /CNW/ - NetraMark Holdings Inc. (the " Company " or " NetraMark ") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF) is pleased to announce a non-brokered private placement financing (the " Offering ") of a minimum of 7,500,000 units of the Company (the " Units "), for aggregate gross proceeds of not less than $1.5 million . Each Unit will consist of one common share in the capital of the Company and one... Read More

TORONTO , July 19, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) is pleased to announce the appointment of Dr. MaryAnne Rizk to its strategic advisory board. With her significant industry experience and expertise, MaryAnne's addition to the advisory board will further strengthen NetraMark's ability to deliver its innovative Artificial Intelligence (AI) based... Read More

TORONTO , July 5, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) announces that it has entered into debt settlement agreements with certain consultants, pursuant to which the Company has agreed to settle an aggregate amount of $240,000 in outstanding debt in exchange for the issuance of 600,000 common shares in the capital of the Company (the "Common Shares")... Read More

TORONTO , June 22, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV) announces that it has entered into an advisor agreement (the "Advisor Agreement") with Dr. Stanley Fenwick (the "Advisor"). Through the Advisor Agreement, the Advisor will provide advice and assistance to the Company, help develop strategies to achieve NetraMark's goals, and facilitate... Read More

TORONTO , June 21, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) ( Frankfurt : 8TV), announces that it has entered into an agreement with ARU Global Inc. ("ARU") to provide public relations services in an effort to increase public awareness of the Company. Certain services to be provided by ARU are anticipated to include "investor relations activities" under the policies of... Read More

TORONTO , June 14, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF), is pleased to announce that it has closed the second and final tranche of its previously announced private placement for gross proceeds of $242,350 (the "Second Tranche"). Netramark issued 655,000 units (each, a "Unit") under the Second Tranche at a price of $0.37 per Unit, with each Unit... Read More

TORONTO , June 9, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF), is pleased to announce that further to its press release of June 1, 2023 and June 6, 2023 , it has closed the first tranche of its previously announced non-brokered private placement for gross proceeds of $500,000 (the "First Tranche"). Netramark issued 1,351,351 units (each, a "Unit") under the... Read More

TORONTO , June 7, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF), is pleased to announce that after a successful application process the Company's common shares will begin trading on the OTCBQ® Market (the "OTCQB") at the opening of the market on June 7, 2023 , under the stock symbol "AINMF". The Company believes that the move to the OTCQB will provide enhanced... Read More

TORONTO , June 6, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF), is pleased to announce increased demand for its private placement financing of up to an additional 675,000 units of the Company (the "Units") at a price of $0.37 per Unit, for additional gross proceeds of up to $250,000 (the "Offering"). Each Unit will consist of one common share in the capital... Read More

TORONTO , June 1, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF) is pleased to announce a non-brokered private placement financing (the "Offering") of up to 1,351,351 units of the Company (the "Units") at a price of $0.37 per Unit, for aggregate gross proceeds of up to $500,000 (the "Offering"). Each Unit will consist of one common share in the capital of the... Read More

TORONTO , June 1, 2023 /CNW/ - NetraMark Holdings Inc . (the "Company" or "NetraMark") (CSE: AIAI) (FSE: 8TV) (OTC: AINMF) announces its attendance at the American Society of Clinical Oncology (ASCO) Conference in Chicago, IL. This prestigious event brings together leading experts, researchers, and professionals from the oncology field to exchange knowledge, discuss advancements, and explore innovative solutions. The... Read More

TORONTO , May 30, 2023 /CNW/ - NetraMark Holdings Inc . (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF) announces participation in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Wednesday, May 31, 2023 , at 12:00 PM EDT and Wednesday, June 7, 2023 , at 1:00 PM PDT . NetraMark welcomes stakeholders, investors, and other... Read More

TORONTO , May 16, 2023 /CNW/ - NetraMark Holdings Inc . (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF) announces the release of NetraGPT. Through newly developed algorithms, NetraGPT builds upon the powerful hypotheses generated from the Company's proprietary Good Clinical Practice (GCP) validated AI/ ML system, NetraAI. The power of the NetraAI system lies in its ability to learn about special... Read More

TORONTO , May 10, 2023 /CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) ( Frankfurt : 8TV) (OTC: AINMF) announces that a NetraMark co-authored paper has been accepted in a peer-reviewed publication (to be included in the next issue of Exploration of Medicine Journal - eISSN: 2692-3106). This peer-reviewed publication further validates the capabilities of the Company's NetraAI technology. In this... Read More

Toronto, ON - TheNewswire - May 5, 2023 - NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE:AIAI) (Frankfurt:8TV) (OTC:AINMF) announces that it has retained the services of Renmark Financial Communications Inc. (“Renmark”) to manage its investor relations activities with financial advisors, portfolio managers, family offices and institutional investors. “We are pleased to announce that we have selected Renmark to... Read More

TORONTO , Jan. 30, 2023 /CNW/ -Today we would like to announce that Nurosene Health Inc. (the "Company" or "NetraMark") (CSE: MEND) ( Frankfurt : 8TV) (OTC: MNNDF) will change our official corporate name to NetraMark Holdings Inc. This will be effective February 1, 2023 and we will continue to trade on the Canadian Securities Exchange (CSE), however, under the new trading symbol "AIAI". "This is reflective of the strategic... Read More

TORONTO , Jan. 18, 2023 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (FSE: 8TV) (OTC: MNNDF) a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry through its wholly owned subsidiary NetraMark, is pleased to announce an advisory relationship with RARE-X, the Global Genes collaborative... Read More

TORONTO , Dec. 6, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) ( Frankfurt : 8TV) (OTC: MNNDF), a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions developed by NetraMark (a wholly owned subsidiary of the Company) announces that Dr. Joseph Geraci , Nurosene's Chief Science Officer, will be participating in the Advancing Drug... Read More

TORONTO , Dec. 1, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) ( Frankfurt : 8TV) (OTC: MNNDF), a company that is focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the pharmaceutical industry, is pleased to share the following business update. "I am pleased to announce that Nurosene has made the strategic decision to focus... Read More